PHVS Pharvaris NV

Pharvaris To Present at the CIIC Fall 2023 Conference

Pharvaris To Present at the CIIC Fall 2023 Conference

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the Consortium of Independent Immunology Clinics (CIIC) Fall 2023 Conference, to be held from October 13-14, 2023, at the Gaylord Texan Resort in Dallas, TX.

Presentation details:

  • Title: Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial

    Presenter: Joshua S. Jacobs, M.D.

    Date/Time: Saturday, October 14, 2023, 1:30-2:15 p.m. CDT (2:30-3:15 p.m. EDT)

    Location: Tate Pre-Function A, Station #1
  • Title: Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule in patients with hereditary angioedema attacks

    Presenter: Michael E. Manning, M.D.

    Date/Time: Saturday, October 14, 2023, 1:30-2:15 p.m. CDT (2:30-3:15 p.m. EDT)

    Location: Tate Pre-Function A, Station #2

Pharvaris is a platinum level sponsor of the CIIC Fall 2023 Conference and will be exhibiting at Booth #2 in the Tate 1-5 Ballroom at the Gaylord Texan Resort. Following the close of the session, the posters will be made available on the Investors section of the Pharvaris website at: .

About Pharvaris

Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit .



Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
EN
04/10/2023

Underlying

PHVSPharvaris NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharvaris NV

 PRESS RELEASE
Free
PHVS PHARVARIS NV

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results ...

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksCash and cash equivalents of €292 million as of December 31, 2025 ZUG, Switzerland, April 02, 2...

April 2, 2026 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and O...

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioede...

March 20, 2026 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Validation of Patient-Reported Outcomes in the On-Demand Treatment of ...

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykin...

March 11, 2026 1 EN
Jacob Mekhael ... (+4)
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Wim Hoste
ACKB ACKERMANS & VAN HAAREN NV
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
PHVS PHARVARIS NV
SYENS SYENSQO
03/03/26 March 3, 2026 1 EN
Jacob Mekhael
  • Jacob Mekhael
PHVS PHARVARIS NV

Pharvaris Presents supportive data for deucrictibant in HAE at AAAAI

Pharvaris presented multiple datasets for deucrictibant in HAE patients in both the on-demand and prophylactic settings at the AAAAI conference. While acknowledging the usual caveats of cross-trial comparison, we believe the data gives deucrictibant a slight edge over Ekterly in the on-demand setting, where a larger proportion of deucrictibant-treated patients achieved onset of symptom relief within 12 hours (90% vs. 76% with Ekterly). In the phase 2 OLE in the prophylactic setting, long term ou...

03/03/26 March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch